Targeted therapies (i.e.: multi-kinase inhibitors, RET, NTRK inhibitors) in advanced disease. 251
HTML-код
- Опубликовано: 15 окт 2022
- Targeted therapies (i.e.: multi-kinase inhibitors, RET and NTRK inhibitors) in advanced thyroid cancer.
Jonathan Wadsley, MA, MRCP, FRCR, Oncologist
Originally presented by @ThyCaInc at the 25th International Thyroid Cancer Survivors' Virtual Conference held in September of 2022.
